- Market Capitalization, $K 121,338,040
- Shares Outstanding, K 2,521,572
- Annual Sales, $ 42,687 M
- Annual Income, $ 14,066 M
- 60-Month Beta 0.56
- Price/Sales 2.94
- Price/Cash Flow 10.36
- Price/Book 1.72
|Period||Period Low||Period High||Performance|
| || |
-3.93 (-7.58%)since 08/27/21
| || |
-5.32 (-10.00%)since 06/28/21
| || |
-3.10 (-6.08%)since 09/28/20
FDA approves Amgen's (AMGN) Repatha for pediatric patients, 10 years of age and older, with familial hypercholesterolemia, both heterozygous and homozygous forms.
Incyte (INCY) obtains FDA approval for the cream formulation of ruxolitinib for the treatment of mild to moderate atopic dermatitis.
/PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of Kadmon Holdings, Inc. (NASDAQ:...
Glaxo (GSK) is seeking approval of Nucala for hypereosinophilic syndrome, eosinophilic granulomatosis with polyangiitis) and chronic rhinosinusitis with nasal polyps in Europe
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of Kadmon Holdings, Inc. (NasdaqGS: KDMN) to Sanofi...
/PRNewswire/ -- is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Kadmon Holdings, Inc. ("Kadmon Holdings" or the "Company") (NASDAQ: KDMN)...
Sanofi (SNY) offers $1.9 billion to buy Kadmon Holdings to strengthen its transplant business. AstraZeneca's (AZN) Ultomiris and Merck's (MRK) Keytruda get approvals for expanded use.
/PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Kadmon Holdings, Inc. (NASDAQ: KDMN) and its board of directors concerning the proposed acquisition of the company...
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the officers or directors of Kadmon Holdings, Inc. (NASDAQ: KDMN) breached their...
Sanofi's (SNY) rilzabrutinib fails to meet the primary endpoint in a phase III study. It was added to its portfolio following the acquisition of Principia Biopharma last year.
|Sanofi-Aventis S.A. ADR|
|Global 100 Ishares ETF|
|Advisorshares Doubleline Value Equity ETF|
|Invesco Nasdaq Next Gen 100 ETF|
|EAFE Min Vol Ishares Edge MSCI ETF|
|Global Healthcare Ishares ETF|
|3rd Resistance Point||48.74|
|2nd Resistance Point||48.48|
|1st Resistance Point||48.19|
|1st Support Level||47.64|
|2nd Support Level||47.38|
|3rd Support Level||47.09|